Anixa Biosciences Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anixa Biosciences şirketinin toplam hissedar öz sermayesi $20.7M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $22.9M ve $2.2M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$20.75m
Eşitlik	US$20.69m
Toplam yükümlülükler	US$2.22m
Toplam varlıklar	US$22.91m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: CY71 'nin kısa vadeli varlıkları ( $22.7M ) kısa vadeli yükümlülüklerini ( $2.0M ) aşıyor.

Uzun Vadeli Yükümlülükler: CY71 şirketinin kısa vadeli varlıkları ( $22.7M ) uzun vadeli yükümlülüklerini ( $213.0K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: CY71 borçsuzdur.

Borcun Azaltılması: CY71 un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: CY71 şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: CY71 serbest nakit akışı her yıl % 7.8 1.4 yıl yetecek nakit akışına sahip olacaktır.

Anixa Biosciences Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Anixa Biosciences, Inc Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the Society for Immunotherapy of Cancer Annual Meeting

Anixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences Appoints Suyasha Gupta as Senior Director of Clinical Development

Anixa Biosciences, Inc. Announces Submission of Protocol Amendment for CAR-T Trial

Lead Independent Director recently bought €78k worth of stock

Anixa Biosciences Announces Japanese Patent on Breast Cancer Vaccine Technology

Anixa Biosciences, Inc. (NasdaqCM:ANIX) announces an Equity Buyback for $5 million worth of its shares.

Anixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial

CEO, Chairman & Co-Chair of CBAB recently bought €56k worth of stock

New major risk - Revenue and earnings growth

Anixa Biosciences, Inc. Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences Welcomes Sanjay Juneja to Its Cancer Business Advisory Board

CEO, Chairman & Co-Chair of CBAB recently bought €89k worth of stock

New major risk - Revenue and earnings growth

Anixa Biosciences, Inc., Annual General Meeting, Mar 21, 2024

Anixa Biosciences, Inc. Announces Japanese Patent on Ovarian Cancer Vaccine Technology

New major risk - Share price stability

New minor risk - Shareholder dilution

New major risk - Share price stability

Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine

Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology

Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology

Anixa Biosciences, Inc. Appoints Mark A. Goldberg, Md, to Its Cancer Business Advisory Board

Anixa Biosciences, Inc. Completes Treatment of First Patient Cohort in Ovarian Cancer CAR-T Clinical Trial

New major risk - Share price stability

Anixa Biosciences, Inc. Establishes Cancer Business Advisory Board

Anixa Biosciences, Inc. Announces Opening of Enrollment for Keytruda® Arm in Ongoing Breast Cancer Vaccine Clinical Trial

Press Release: Anixa Biosciences Announces Notice of Allowance of Additional Patent on Ovarian Cancer Vaccine Technology

Now 40% undervalued after recent price drop

Anixa Biosciences, Inc., Annual General Meeting, Mar 09, 2023

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Anixa Biosciences Announces Maximum Tolerated Dose Reached in Trial of Preventative Breast Cancer Vaccine

Insufficient new directors

Insufficient new directors

Anixa Biosciences Inc. Announces Commencement of Phase 1B Trial of Its Breast Cancer Vaccine At Cleveland Clinic

Anixa Biosciences Announces Treatment of First Patient in Its Ovarian Cancer Car-T Clinical Trial

Anixa Biosciences, Inc. Announces Management Changes

Anixa Biosciences, Inc. Announces the Initiation of its Ovarian Cancer CAR-T Phase 1 Trial at Moffitt Cancer Center

Anixa Biosciences, Inc., Annual General Meeting, Mar 10, 2022

Anixa Biosciences, Inc., Annual General Meeting, Mar 10, 2022

Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine

Anixa Biosciences and MolGenie Announce Early Potency Analysis of SARS-CoV-2 Protease Inhibitor

Chairman recently bought €53k worth of stock

Anixa Biosciences and Molgenie Announce That Their Covid-19 Compounds Are Expected to Be Effective Against the Omicron Variant

Lead Independent Director recently bought €75k worth of stock

Anixa Biosciences' Covid-19 Compounds Expected to Be Effective Against the Delta Variant

Anixa Biosciences, Inc. Announces Issuance of U.S. Patent for Ovarian Cancer Vaccine Technology

Board Member recently bought €70k worth of stock

Lead Independent Director recently bought €73k worth of stock

Independent Director has left the company

Independent Director has left the company

Anixa Biosciences, Inc Receives Additional Information Request from US FDA for CAR-T IND Application

Lead Independent Director recently bought €185k worth of stock

New 90-day high: €4.72

Anixa Biosciences, Inc. Announces European Patent Issued for Its CAR-T Cancer Therapy

Anixa Biosciences, Inc. Begins Animal Testing of Covid-19 Therapeutic Candidates

New 90-day high: €3.88

New 90-day high: €2.68

Anixa Biosciences and Cleveland Clinic Announce FDA Clearance to Initiate Clinical Trial of Breast Cancer Vaccine

Anixa Biosciences, Inc. Covid-19 Therapy Demonstrates Comparable Potency to Remdesivir in Pre-Clinical Testing

New 90-day high: €2.46

Anixa Biosciences, Inc. Announces Licensing Agreement with Cleveland Clinic for Ovarian Cancer Vaccine Technology

Lead Independent Director recently bought €70k worth of stock

New 90-day low - €1.67

Anixa Biosciences, Inc.(NasdaqCM:ANIX) dropped from Russell Microcap Value Index

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin